Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Neurotoxicity Syndromes 2Lung Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Paresthesia 1Ovarian Neoplasms 1Neutropenia 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1Breast Diseases 1Anemia 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms × 2,2'-dithiodiethanesulfonic acid × Clear all
NCT00039780 2022-07-13

Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel

BioNumerik Pharmaceuticals, Inc.

Phase 3 Completed
764 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Paresthesia, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡